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Abstract
Context: Hyperthyroidism can lead to reduced bone mineral density (BMD) and increased fracture risk particularly
in postmenopausal women, but the mechanism behind is still unclear.
Objective: Prospective examination of the influence of thyroid hormones and/or thyroid autoantibodies on BMD
in premenopause.
Design: We have examined 32 premenopausal women with untreated active Graves’ disease from time of
diagnosis, during 18 months of antithyroid drug therapy (ATD) and additionally 18 months after discontinuing ATD.
Variables of thyroid metabolism, calcium homeostasis and body composition were measured every 3 months. BMD
of lumbar spine and femoral neck were measured at baseline, 18 ± 3 and 36 ± 3 months. Data were compared to
base line, a sex- and age matched control group and a group of patients with Hashimoto’s thyroiditis treated with
non-suppressive doses of levothyroxine.
Results: The study showed significantly (p < 0.002) lower BMD in the thyrotoxic state compared to the control
group with subsequent significant improvement during 18 ± 3 months of ATD compared to baseline (p < 0.001).
However, during the following 18 months after stopping ATD femoral neck BMD decreased again unrelated to age
(more than 0.4% per year, p < 0,002). The wellestablished effect of thyrotoxicosis on calcium homeostasis was
confirmed. The positive predictor for best BMD was TSH receptor antibodies (TRAb) while free T4 correlated
negatively in the thyrotoxic female Graves’ patients (p < 0.02 and p < 0.003). In healthy controls and patients with
treated Graves’ disease both TSH and T4 correlated negatively to the bone mass (BMC) (p < 0.003).
Conclusion: The results indicated a clinically relevant impact of thyroid function on bone modulation also in
premenopausal women with Graves’ disease, and further indicated the possibility for a direct action of TRAb on
bones.
Introduction
Thyroid hormones are known to stimulate bone turn-
over [1], and previous studies have shown decreased
bone mineral density (BMD) [2] and increased risk of
osteoporotic fractures [3-5] in patients with thyrotoxico-
sis [6]. However, many studies have been composed of a
mixture of patients with different diagnoses (Graves’ dis-
ease, toxic multinodular goiter, toxic solitary adenoma)
and different patient characteristics (males,
premenopausal females, postmenopausal females).
Although all of these different thyroid diseases result in
hyperthyroidism, as does also overtreatment with thyr-
oid hormone replacement, the aetiologies and the course
of the diseases are highly different. The extent and long-
term reversibility of bone loss may therefore well
depend on the aetiology of hyperthyroidism, but also on
age and gender of the patients. A previous cross-sec-
tional study of males and females with Graves’ disease,
found low BMD in women, but not in men [7], whereas
a recent cross-sectional study also described low BMD
in male patients with Graves’ disease [8]. Menopause
could theoretically aggravate the bone loss in
* Correspondence: ufeldt@rh.dk
1Department of Endocrinology, National University Hospital, Rigshospitalet,
Copenhagen, Denmark
Full list of author information is available at the end of the article
Belsing et al. Nutrition & Metabolism 2010, 7:72
http://www.nutritionandmetabolism.com/content/7/1/72
© 2010 Belsing et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.thyrotoxicosis due to a synergistic effect of hypogonad-
ism and excess thyroid hormone levels. However, the
skeletal responsiveness to short-time stimulation with
thyroid hormones in vivo has been demonstrated to be
unaffected by menopausal status [9]. Furthermore, a
cross-sectional study found no interaction between the
effects of menopausal status and thyroid disease on
BMD [10].
A few longitudinal studies have evaluated bone mass
recovery after treatment of thyrotoxic women, demon-
strating an only partly reversible bone loss [11-14]. In
general, these previous studies were small, and one
long-term study has shown a significant 11% increase in
lumbar spine BMD three years after obtaining euthyr-
oidism [15]. However, there is no complete concordance
on the influence of thyrotoxicosis and antithyroid drug
therapy on bone.
We chose to study a group of hyperthyroid patients
with a single aetiology, namely Graves’ disease, which is
an autoimmune disease, and as one of the control
groups we therefore chose another autoimmune thyroid
disease, Hashimoto’s thyroiditis, characterised by devel-
opment of chronic hypofunction, which is then replaced
with synthetic thyroid hormone. The aim of this pro-
spective study was thus to evaluate long-term reversibil-
ity of BMD in premenopausal female patients with
Graves’ disease, during antithyroid drug therapy (ATD)
and after discontinuation of the therapy, compared with
an age-matched group of euthyroid female patients with
Hashimoto’s thyroiditis on stable and correct thyroxine
replacement, and a female control group.
Materials and methods
Thirty-two female premenopausal women newly diag-
nosed with Graves’ disease and 18 euthyroid premeno-
pausal patients with Hashimoto’s thyroiditis treated with
non-suppressive doses of levothyroxine (Eltroxin®) for a
mean of 43 months (range: 0-360) were enrolled conse-
cutively in the present prospective study. Nineteen
healthy premenopausal women without thyroid disease
or family history of thyroid disease served as age-
matched controls. All were examined at the Department
of Endocrinology, National University Hospital, Rigshos-
pitalet, Denmark (Table 1).
Thyrotoxicosis was diagnosed by a high (above refer-
ence range) total thyroxine (T4) (reference range:
60-140 nmol/l), free thyroxine (fT4) (reference range:
9.1-23.8 pmol/l), total triiodothyronine (T3) (1.5-2.7
nmol/l) and/or free T3 (fT3) (reference range: 2.2-5.4
pmol/l) combined with low thyrotropin (TSH) (below
detection limit) (reference range: 0.5-4.2 mU/l).
Five patients with Graves’ disease had thyroid asso-
ciated ophthalmopathy (TAO), one of whom was treated
with a short course of prednisolone, 5 got pregnant
during the study period (2 gave birth and 3 had an
abortion), 14 were smokers and 1 was on birth-control
pills. Eight patients with Hashimoto’s thyroiditis were
smokers and 1 on birth-control pills. In the control
group there were 2 smokers and none was taking birth-
control pills (Table 1). Neither patients nor controls had
other concomitant diseases. The characteristics of the
patients and controls are shown in Table 1.
The patients with Graves’ disease were included in the
study at diagnosis with baseline measurements before
starting ATD, while all started treatment with beta-
blocker (Propranolol®) for ethical reasons. The patients
with Graves’ diseases were otherwise treated solely with
thiamazol (Thycapzol® range: 2.5-20.0 mg per day).
Patients with Hashimoto’s thyroiditis continued their
usual dose of levothyroxin (Eltroxin® range: 50-200 µg,
mean 1.45 μg/kg daily).
The patients with Graves’ disease were examined every
3 months during an 18 months course of ATD followed
by additional 18 months after stopping ATD (standard
treatment regimen of the department). In case of relapse
during the additional 18 months follow-up the patients
were subsequently excused from the study. Patients with
Hashimoto’s thyroiditis and the normal healthy controls
were investigated once.
All participants were seen in the outpatient clinic after
an overnight of fasting. Serum levels of T4, fT4 T3, fT3,
TSH, TSH receptor autoantibodies (TRAb), anti-thyroid
peroxidase antibodies (anti-TPO), parathyroid hormone
(PTH), total calcium (mmol/L) and Ca
2+ (mmol/L) were
measured as well as urinary calcium excretion (mmol/24
hours) and body mass index (BMI, weight/height
2).
Body composition, as well as BMD and bone mineral
content (BMC) of the femoral neck and lumbar spine
were measured by Dual Energy X-ray Absorptiometry
(DEXA). Serum and urine markers, BMI and body com-
position measurements were reported at 4 time points:
baseline, 3 months, 18 ± 3 months and 36 ± 3 months.
BMD and BMC of columnar spine and femoral neck
were measured at 0, 18 ± 3 and 36 ± 3 months.
Thyroid hormones and antibodies
Serum concentrations of TSH and peripheral thyroid
hormones were measured by commercially available
kits at the Clinical Biochemical Laboratory, National
University Hospital, Rigshospitalet including serum
concentrations of TSH measured by time resolved
fluoroimmunoassay, (hTSH Ultra, Wallac, Turku,
Finland), T4 by fluorescence polarization immunoassay
(IMX
R, Abbott Laboratories Diagnostics Div., Illinois,
USA), and T3 by microparticle enzyme immunoassay
(IMX
R, Abbott).
The 2
nd generation DYNOtest TRAK® (Brahms, Berlin,
Germany) measures quantitatively antibodies against the
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i n gt oW H Os t a n d a r d9 0 / 6 7 2 .V a l u e sb e l o w1 . 0I U / l
were defined as negative, values above 1.5 IU/l positive
and values between 1.0-1.5 IU/l considered questionably
positive [16]. Samples from one subject were run in the
same assay. The intra-assay coefficient of variation (CV)
o f3s a m p l e so f1 . 3 5 ,6 . 2a n d2 9I U / Lw e r e1 5 ,4a n d
5%, respectively, and the inter-assay CV of 3 samples of
1.5, 21 and 29 IU/L were 15, 8 and 8%, respectively [17].
Anti-TPO was measured in duplicate by a lumines-
cence immuno assay (LUMItest, BRAHMS Diagnostica,
Berlin) at the Serum Institute, Department of Autoim-
munity. All samples from one subject were run in the
same assay. The range of the calibration curve was 60 to
3000 U/L [18].
PTH and calcium assessments
PTH was measured in our laboratory as previously
described [19,20]. Alkaline phosphatases (reference
range: 80-275 U/L) were measured routinely by the
Clinical Biochemical Laboratory, National University
Hospital, Rigshospitalet as was total serum calcium
(reference range: 2.2-2.6 mmol/L) and Ca
2+ (reference
range: 1.15-1.35 mmol/L) using an ion-selective elec-
trode (Konelab 30i, Thermo) and with a between run
CV = 3%.
Patients and normal controls collected urine for 24
hours before each appointment. Calcium excretion
(mmol/24 hour) was measured and creatinine clearance
calculated (reference range: 0.8-2.5 ml/sec) by the
Clinical Biochemical Laboratory, National University
Hospital, Rigshospitalet.
Lipid profile
Total cholesterol (reference range: 4.0-7.3 mmol/L), LDL
cholesterol (0.9-1.9 mmol/L), HDL cholesterol (2.7-4.1
mmol/L) and triglycerides (0.5-2.20 mmol/L) were mea-
sured by the Clinical Biochemical Laboratory, National
University Hospital, Rigshospitalet using an enzymatic
colorimetric tests (MODULAR, P-modul, Roche) and
with a between run CV = 5%.
DEXA scans
DEXA measurements of body composition were per-
formed as whole body scans using the Norland XR-26
MarkII/HS (Norland Corporation, WIS) with high-speed
dynamic filtration as previously described [21]. Three
compartments were measured separately: Total bone
mass (BMC), total fat mass (TFM) and total lean body
mass (TLM) the sum of which gives the total body
weight. The accuracy was 0.2 kg for total soft tissue and
0.001 kg for the fat mass. During the study period the
scanner was equilibrated daily against a phantom pro-
vided from the manufacturer [22,23]. BMD, correspond-
i n gt oB M C( i ng )r e l a t e dt ot h ea r e ao ft h eb o n ea n d
thus given in g/cm
2, was calculated separately at the left
femoral neck and lumbar spine (L2-L4). The femoral
neck T-scores (number of SDs above or below young
adult mean BMD) and Z-scores (number of SDs above
or below the age-matched mean BMD) were based upon
Table 1 Demographic data of premenopausal female patients with Graves’ disease compared to both healthy controls
and patients with Hashimoto’s thyroiditis on stable levothyroxine replacement
Controls Graves’ disease Months after diagnosis Hashimoto’s thyroiditis
Study points (months) Baseline 3 18 ± 3 36 ± 3
Number 19 32 18
Age (years) 43 39
NS 43
NS
(37-49) (34-45) (36-50)
Height (m) 1.67 1.66
NS 1.66
NS
(164-170) (164-169) (162-170)
Weight (kg) 67 59
# 63* 65** 65** 67
NS
(62-73) (55-63) (59-67) (61-70) (61-70) (63-71)
BMI (kg/m
2)2 4 2 1
# 23* 23** 23** 24
NS
(22-26) (20-23) (21-24) (22-25) (22-25) (22-26)
Pregnancies (no) 0 5 0
Abortions (no) 0 3 0
Smoking (no) 2 14 8
Birth control tablets (no) 0 1 1
Calcium tablets (no) 0 1 0
TAO (no) 0 5 0
Prednisone (no) 0 1 0
Data are expressed as antilog mean (CI 95%) and significance is marked as * = p < 0.05,
** = p < 0.005 when compared to baseline and marked differently as
# = p < 0.05,
## = p < 0.005 when normal controls are compared to baseline data for patient
with Graves’ disease or patients with Hashimoto’s disease. NS = non-significant. No=number of persons. TAO=thyroid associated ophthalmopathy.
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software provided by the factory [24,25]. The same
laboratory technician performed all scans with an intra-
operator variation of 5%. Height and weight were mea-
sured and BMI (kg/m
2) was calculated.
Statistics
Serum concentrations of thyroid hormones, thyroid
antibodies, PTH, calcium, and body composition were
not distributed normally, and therefore results were
log10 transformed before parametric analyses. Z- and T-
scores were not transformed. Differences between the
normal control group and patients were measured using
student’s t-test. Differences from baseline (each patient
being her own control) were tested using a one-way one
factor repeated measures ANOVA and post hoc testing
using both Newman-Keuls and/or Duncan’sm u l t i p l e
range test. Multiple regression tests (forward stepwise)
were performed to investigate possible predictors for
BMD. Back transformed data are presented as mean and
95% confidence interval (CI 95%). By post hoc analyses
32 patients in each group were statistically sufficient to
demonstrate a 10% difference in BMD between groups
with a p-value of <0.02, and longitudinally within
patients with a p-value of < 0.01. The analyses were per-
formed using Statistica version 6.1, StatSoft Inc, USA.
Ethical considerations
All participants gave their written informed consent.
The study was in accordance with the Helsinki declara-
tion and all protocols were approved by the Danish
Local Ethical Committee of Copenhagen, Denmark
(approval no: KF-094/95, KF-247/98) as well as the
Registration Committee (approval no: 1995-1200-133).
Results
Thyroid function and autoantibodies
Patients with Graves’ diseases had had self-reported
symptoms of thyrotoxicosis for a mean of 7 months (CI
95%, 5-10) before the time of diagnosis. At diagnosis the
mean T4 level was 246 nmol/l (231-263), T3 was 5.4
nmol/l (4.6-6.3) and TSH was (< 0.01 mU/l (< 0.01-
0.02)) (Table 2). Most patients with Graves’ diseases
obtained euthyroidism within 3 months. The patients
were euthyroid after 18 ± 3 months of ATD with a
mean T4 level of 98 nmol/l (91-105), T3 of 1.5 nmol/l
(1.4-1.7) and TSH of 1.12 mU/l (0.67-1.88) (Table 2).
TRAb and anti-TPO decreased significantly from 7
IU/L (5-11) at baseline to 1 IU/L (1-2) p < 0.00005 and
from 292 IU/L (166-513) at baseline to 174 IU/L (107-
282) p < 0.02, respectively. Patients with Hashimoto’s
thyroiditis had been treated with T4 for a mean of 43
months when entering the study and were euthyroid
and with positive anti-TPO (1452 IU/L (785-2686)
(Table 2).
Body composition and lipid profile
The body weight of the patients with Graves’ disease
increased 6 kg (p < 0.00006 by conventional method)
and 7 kg by DEXA measurement (p < 0.00005) 36 ± 3
months after start of ATD. The increased weight was
mainly caused by an increase in muscle tissue, since
TLM increased 4 kg (p < 0.00005), TFM only 3 kg (p <
0.003) and BMC 0.2 kg (p < 0.02) (data not shown).
The 3 fractions of cholesterol were lower and trigly-
ceride higher when baseline values for the patient with
Graves’ disease were compared to the control group
(data not shown). Patients with Hashimoto’s thyroiditis
had significantly higher triglyceride concentrations com-
pared to the control group, but similar cholesterol
levels. During the 36 ± 3 months study period the total,
HDL and LDL cholesterol increased in patients with
Graves’ d i s e a s e( p<0 . 0 0 0 1 )w h i l et r i g l y c e r i d e s
decreased (p < 0.0004) (data not shown).
Calcium assessments
In general, total serum calcium, Ca
2+ and calcium excre-
tion were high at diagnosis of Graves’ disease and
decreased during 36 ± 3 months follow-up (Table 3).
PTH increased significantly from 23 pg/ml (16-34)
(mean (CI 95%)) to 39 pg/ml (25-59) at the end of ATD
at 18 ± 3 months (p < 0.02). Serum Ca
2+ decreased sig-
nificantly from 1.32 mmol/L (1.31-1.34) to 1.25 mmol/L
(1.23-1.26) (p < 0.0001). Urinary calcium excretion
decreased significantly from 5.2 (4.1-6.5) to 2.8 mmol/24
hours (2.2-3.7) (p < 0.0001) after 3 months and
increased to 4.0 mmol/24 hours (3.1-5.2) after 36 ± 3
months follow-up. Alkaline phosphatases were all the
time within the reference range (80-275 U/L) but in the
upper end at diagnosis, increasing significantly to 251
U/L (218-288) during the first 3 months of ATD and
fell again after 18 ± 3 and 36 ± 3 months (Table 3). The
patients with Graves’ disease had a normal creatinine
clearance at all measuring points (Table 3). No signifi-
cant differences were found in the patients with Hashi-
moto’s thyroiditis (Table 3).
Bone status
The patients with Graves’ disease had low whole body
BMD (g/cm
2), lumbar spine and femoral neck measure-
ments at baseline compared to controls and all measure-
ments increased significantly (p < 0.002) during the 18 ±
3 months of treatment with ATD (table 4, Fig 1).
Femoral neck BMD (g/cm
2), Z-scores and T-scores
decreased significantly again (p < 0.001) after disconti-
nuing ATD. Similar reductions were seen in BMC (Fig
1). The reduction was more than the expected age-
related decrease (i.e. 0.4% per year) [25]. Few patients,
however, fulfilled the criteria for osteopenia and/or
osteoporosis. No significant differences were found
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the patients with Graves’ disease, but there was a ten-
dency towards low values in both groups compared to
the control group (Table 4).
Multiple regressions for BMD and BMC
Stepwise multiple regressions were performed to esti-
mate the strongest predictor for whole body BMD and
BMC. The model included age, BMI, Ca
2+,a l k a l i n e
phosphatase, cholesterol, HDL, LDL, triglyceride, TSH,
total T4, fT4, total T3, fT3, TRAb and anti-TPO. In the
normal control group the best negative predictor for
BMD was TSH (b = -0.49, p < 0.03) and for BMC it
was both TSH (b = -0.52, p < 0.03) and total T4 (b =
-0.42, p < 0.03). This pattern was neither found in the
patients with newly diagnosed Graves’ disease nor in the
patients with Hashimoto’s thyroiditis. The best predic-
tors for BMD in patients with Graves’ disease were a
Table 2 Profile of the thyroid function and thyroid autoantibodies of premenopausal female patients with Graves’
disease compared to both healthy controls and patients with Hashimoto’s thyroiditis on stable levothyroxine
replacement
Controls Graves’ disease Months after diagnosis Hashimoto’s thyroiditis
Study points (months) Baseline 3 18 ± 3 36 ± 3
Number 19 32 18
TSH (mU/L) 1.5 < 0.01
## 0.2** 1.1** 0.6** 1.2
NS
(1.3-1.7) (< 0,01-0.02) (0.1-0.5) (0.8-1.9) (0.4-1.0) (0.4-3.7)
T4 (nmol/L) 91 246
## 93** 98** 103** 105
NS
(84-98) (231-263) (76-115) (91-105) (92-115) (92-120)
fT4 (pmol/L) 14 51
## 15** 14** 15** 16
NS
(14-15) (45-56) (13-18) (13-15) (14-16) (14-18)
T3 (nmol/L) 1.5 5.4
## 1.8** 1.5** 1.5** 1.6
NS
(1.3-1.7) (4.6-6.3) (1.5-2.2) (1.4-1.7) (1.3-1.7) (1.5-1.8)
fT3 (pmol/L) 5.2 24
## 5.8** 4.6** 4.2** 5.7
NS
(4.7-5.8) (19-30) (4.6-7.2) (4.3-4.9) (3.8-4.8) (4.9-6.7)
TRAb (< 1.0 < 1.0 7.3
## 4.1** 2.0** 1.2** < 1.0
IU/L) (4.9-10.8) (2.6-6.2) (1.3-2.9) (0.8-1.8)
Anti-TPO < 60 292
## 206
NS 174* 249
NS 1452
##
(< 60 IU/L) (166-513) (121-349) (107-282) (143-435) (785-2686)
Data are expressed as antilog mean (CI 95%) and significance is marked as * = p < 0.05, ** = p < 0.005 when compared to baseline and marked differently
as
# =p<0 . 0 5 ,
## = p < 0.005 when normal controls are compared to baseline data for patients with Graves’ disease or patients with Hashimoto’s disease.
NS = non-significant.
Table 3 Calcium assessments of premenopausal female patients with Graves’ disease compared to both healthy
controls and patients with Hashimoto’s thyroiditis on stable levothyroxine replacement
Controls Graves’ disease Months after diagnosis Hashimoto’s thyroiditis
Study points (months) Baseline 3 18 ± 3 36 ± 3
Number 19 32 18
PTH
¤ (pg/ml) 39 23
NS 32* 39* - 32
NS
(22-72) (16-34) (22-46) (25-59) (13-83)
Calcium (mmol/L) 2.23 2.42
## 2.30** 2.27** 2.31** 2.23
NS
(2.19-2.28) (2.38-2.46) (2.27-2.34) (2.24-2.29) (2.28-2.35) (2.24-2.35)
Ca
2+ (mmol/L) 1.21 1.32
## 1.23** 1.24** 1.25** 1.26
NS
(1.20-1.23) (1.31-1.34) (1.22-1.26) (1.23-1.25) (1.23-1.26) (1.16-1.38)
Alkaline phosphatase 136 223
## 251
## 180**,
# 160** 150
NS
(U/I) (120-155) (199-249) (218-288) (159-204) (141-180) (126-179)
Urinary Calcium (mmol) 4.1 5.2
NS 2.8** 3.6
NS 4.0
NS 3.4
NS
(2.9-5.9) (4.1-6.5) (2.2-3.7) (2.9-4.5) (3.1-5.2) (2.6-4.5)
Creatinine Cl. (ml/sec) 1.3 1.2
NS 1.3
NS 1.2
NS 1.3
NS 1.1
NS
(1.2-1.5) (1.1-1.4) (1.2-1.4) (1.1-1.4) (1.1-1.5) (1.0-2.3)
Data are expressed as antilog mean (CI 95%) and significance is marked as * = p < 0.05, ** = p < 0.005 when compared to baseline and marked differently
as
# =p<0 . 0 5 ,
## = p < 0.005 when normal controls were compared to baseline data for patient with Graves’ diseases or patient with Hashimoto disease.
NS = non-significant. ¤ = N varied from 4-11.
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a positive one with TRAb (b = 0.41, p < 0.02) while no
significant predictors were found for BMC in this group
(data not shown).
Discussion
In this prospective study we have examined the bone
metabolism in 32 premenopausal women with untreated
active Graves’ disease from time of diagnosis, during 18
months of ATD and to approximately 18 months after
discontinuing their ATD. In order to avoid too many
confounders and get a more uniform patient group than
those previously studied we chose only females (males
were excluded from this study due to their different
body-composition compared to females), and only in
premenopause (to avoid the postmenopausal bone loss),
and only patients with the autoimmune Graves’ disease.
The obtained results and conclusions thus only apply to
patients with these characteristics and cannot be extra-
polated to all hyperthyroid patients. We measured thyr-
oid and calcium parameters as well as BMC and BMD
by DEXA scan with calculation of Z-scores and T-
scores. Data were compared to baseline, an age matched
control group and a group of patients with Hashimoto’s
thyroiditis (a different autoimmune thyroid disease) on
non-suppressive doses of levothyroxine substitution in
order to avoid suppressive effects from levothyroxine
substitution on bones. The study showed significantly
reduced whole body BMD in the thyrotoxic state com-
pared to the control group, which improved significantly
during 18 ± 3 months of ATD and 18 ± 3 months of
post-ATD follow-up compared to baseline. However, 18
± 3 months after stopping ATD femoral neck variables
had decreased again probably due to a slightly higher
level of thyroid hormones with a still decreased TSH as
one possibility or an age related decline as another.
However, the reduction was more than the estimated
2% age related decline as shown by Leslie et al [25] indi-
cating an additional pathophysiological effect in the
patients. In parallel, the well established negative cal-
cium balance in hyperthyroidism [1] also improved with
a decrease in serum calcium and urinary calcium excre-
tion and an increase in PTH during ATD. At the time
of thyrotoxicosis, we found that TRAb and fT4, reflect-
ing the degree of autoimmune hyperthyroidism, were
strong but opposite predictors of BMD.
The first case of thyrotoxic osteopathy was reported in
1891 by von Recklinghausen [26]. Since then numerous
studies have addressed this issue, but for a variety of
reasons many of them were not able to clarify the effects
of thyroid hormones on skeletal integrity [27]. In gen-
eral, the published clinical studies used different study
designs such as a variable inclusion of men and pre-
and postmenopausal women; the case-control studies
Table 4 Bone status (bone mineral density, BMD) of premenopausal female patients with Graves’ disease compared to
both healthy controls and patients with Hashimoto’s thyroiditis on stable levothyroxine replacement
Controls Graves’ disease Months after diagnosis Hashimoto’s thyroiditis
Study points (months) Baseline 18 ± 3 36 ± 3
Number 19 32 18
whole body BMD
Z-score 0.3 -0.2
# -0.1** 0.1** 0.2
NS
(-0.1 - 0.7) (-0.5 - 0.1) (-0.7 - 0.5) (-0.5-0.6) (-0.2 - 0.5)
T-score 0.1 -0.5
NS -0.1** -0.3** -0.1
NS
(-0.4 - 0.5) ((-0.9) - (-0.1)) (-0.7 - 0.5) (-0.9 - 0.3) (-0.4 - 0.3)
Lumbar spine BMD
Z-score 0.6 -0.1
NS 0.5** 0.6** 0.3
NS
(0.1-1.2) (-0.6 - 0.6) (-0.3 - 1.2) (-0.4 - 1.6) (-0.2 - 0.8)
T-score 0.1 -0.7
NS 0.1** -0.2** -0.4
NS
(-0.5 - 0.8) ((-1.4) - (-0.1)) (-0.8 - 0.9) (-1.3 - 0.9) (-0.9 - 0.1)
Femoral neck BMD
0.91 0.83
NS 0.91* 0.84* 0.86
NS
(0.84-0.98) (0.77-0.90) (0.8-1.0) (0.75-0.94) (0.82-0.90)
Z-score 0.5 -0.2
# 0.3** 0.1** 0.1
NS
(0.04-0.95) (-0.5 - 0.3) (-0.3 - 0.9) (-0.5 - 0.6) (-0.4 - 0.5)
-
T-score -0.1 -0.6
NS 0.1** -0.6* -0.5
NS
(-0.6 - 0.5) ((-1.1) - (-0.1)) - (-0.6 - 0.7) (-1.3 - 0.2) ((-0.8) - (-0.2))
Z-scores and T-scores are expressed as (mean (CI 95%)) and significance is marked as * = p < 0.05, ** = <0.005 when compared to baseline and marked
differently as
# = p < 0.05,
## = p < 0.005 when normal controls are compared to baseline data for patients with Graves’ diseases or patients with Hashimoto’s
disease. NS = non-significant.
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Page 6 of 10have not been consistently and appropriately matched;
both thyroid replacement and suppression therapies
have gradually been changed over the last 20 years mak-
ing results from present studies difficult to compare
with historical data; different methods for assessment of
BMD have been used and measurement of various ske-
letal sites using different techniques often produced
incomparable results; finally, in one of the studies
patients with heterogeneous thyroid diseases were inves-
tigated [27].
Recently, a large population based case-control study
of 124,655 persons found an increased fracture risk in a
subgroup of thyroid patients within 5 years from the
diagnosis of hyperthyroidism and within 10 years from
the diagnosis of hypothyroidism, thus supporting the
notion that thyroid function is important for bone
health [28]. However, several relevant confounders,
known to affect bone mineral content and density, such
as body weight and smoking were not taken into
account.
Figure 1 Measurements of whole body (A), lumbar spine (B) and femoral neck (C) bone mineral content (BMC) (kg) as well as whole
body (D), lumbar spine (E) and femoral neck (F) bone mineral density (BMD) (g/cm
2) in female normal controls, patients with
Hashimoto’s thyroiditis and premenopausal women with Graves’ diseases during 36 ± 3 months follow-up (at baseline, 3 and 18 ± 3
months on antithyroid drug therapy and additional 18 ± 3 months without antithyroid drug thyroid therapy or to relapse).+
Represents back transformed mean. Significant differences to baseline (B) or to control group (N): * = p < 0.05 and ns = non significant.
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were rather homogeneous. All were premenopausal
women diagnosed at the first onset of Graves’ thyrotoxi-
cosis, and followed prospectively up to 36 ± 3 months
after the diagnosis, and all were given a titration dose of
thiamazole. They were furthermore compared to an age,
gender and BMI matched control group. However,
despite careful monitoring of the patients to maintain
euthyroidism on ATD it cannot be excluded that the
patients had shorter periods of thyroid dysfunction dur-
ing or after the treatment with ATD, although this is
less likely to occur in patients with Graves’ disease than
in multinodular goitres or toxic adenomas. It is, how-
ever, not a probable explanation for the reduction in
BMD at the femoral neck between stopping ATD at
18 ± 3 and 36 ± 3 months. In addition, it cannot be
excluded that confounders such as pregnancies, abor-
tions, prednisolone, birth-control pills, other estrogens
and smoking may have influenced the result. Overall,
however, BMD was significantly decreased at the time of
diagnosis and increased during ATD which is in keeping
with previous studies [27,28].
The mechanisms for the decreased BMD in patients
with hyperthyroidism have been shown to include an
increased bone turnover, leading to a negative bone
balance, with consequent expansion of the remodelling
space, a decreased cortical thickness [28-30], and
increased risk of trabecular perforations [1] The effects
of thyroid hormones on bone turnover are presumably
at least in part mediated by thyroid hormone receptors
(TR) [31] although the molecular mechanisms are still
unclear (30). TSH may influence bone turnover
directly, since both high levels of endogenous TSH
[28,32-34] and injection of recombinant TSH (Thyro-
gen®) [35] have been demonstrated to inhibit bone
resorption and TSH receptors have been found on
human osteoblasts [36]. TSH might also stimulate the
expression of type 2 iodothyronine deiodinase in osteo-
blasts [37]. Thus, suppressed TSH levels as seen in
hyperthyroidism might contribute to bone loss. How-
ever, Bassett and his group recently demonstrated in
mice that bone loss in thyrotoxicosis was independent
of circulating TSH levels and predominantly mediated
by TRa [38]. Thus, additional studies are required to
confirm the diffential role of TSH and/or T3 in thyro-
t o x i cb o n et u r n o v e r .
In the present study TSH and T4 levels were both
negatively associated with BMD in healthy controls, pos-
sibly reflecting a physiological regulation of bone meta-
bolism by TSH stimulating T4 production. Population
studies have found conflicting results. Morris suggested
ab o n ep r o t e c t i v er o l ef r o mT S Hi np o s t m e n o p a u s a l
women [39], while Griemnes et al found no association
between TSH and BMD [40].
Conversely, at the time of overt hyperthyroidism fT4
and TRAb displayed opposite relationships, supporting
the notion that high thyroid hormone levels reduced
BMD, while TRAb might protect from bone loss
through its effect on the TSH receptor. These results
contradicted those of Majima et al who studied 56 Japa-
nese male patients with newly diagnosed hyperthyroid
Graves’ disease and found that both TRAb as well as T4
correlated negatively with a reduction in BMD [7,32,37].
This finding was, however, in keeping with Wakasugi et
al [41] and Jodar et al [42] previously demonstrating a
significantly negative correlation between TRAb and
lumbar BMD in hyperthyroid patients, and Kumeda
et al [43] reported that TRAb did not correlate with
either fT3 or fT4, but correlated closely with bone meta-
bolic markers in Graves’ disease. Other studies have
suggested that the past history of Graves’ disease itself,
and not the current thyroid function, was responsible
for bone loss in women receiving long-term levothyrox-
ine therapy [7,27].
There are thus several indications of a direct anabolic
effect of TRAb on bone metabolism but it is yet not
clear whether it reflects the hyperthyroid state or is pre-
sent regardless of the thyroid function [7,41,43]. The
other correlations on thyroid function effects on bones
found in the present and some other studies are not
readily explainable. Yet, it must be appreciated that
hyperthyroidism not only affects thyroid hormone pro-
duction, but also the metabolism of binding proteins
and the activity of deiodinases [44]. Measurement of
both total and free thyroid hormones will therefore be
very method dependant, and in an unpredictable man-
ner, which could invalid results and thus also correla-
tions [45]. Finally, it cannot be excluded that the
increase in muscle mass after attainment of euthyroid-
ism can contribute mechanically to an increase in BMD/
BMC [reviewed in [46]].
In summary, we found that bone mass and density
were significantly reduced in premenopausal women
with newly diagnosed Graves’ disease with a marked
improvement during ATD. At time of diagnosis serum
calcium levels and calcium excretion were increased and
PTH was decreased, as indicators of accelerated bone
turn over, all of which normalised during ATD. The
best predictors for BMD were opposite relationships to
TRAb and fT4, respectively in the thyrotoxic female
Graves’ patients, and TSH alone in the control group.
Although the mechanisms cannot be explained by the
present results, they did indicate an important impact of
both thyroid function and TRAb on bone modulation
not only in postmenopausal, but also in premenopausal
women. Attainment of euthyroidism partly reversed the
adverse effect of hyperthyroidism on bones. This is a
very important clinical finding, which will have an
Belsing et al. Nutrition & Metabolism 2010, 7:72
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Page 8 of 10impact on the general management of these patients.
However, longer follow-up studies in hyperthyroid
patients of other aetiologies and more experimental stu-
dies in cells or animals will be required to clarify the
mechanisms for bone reversibility in patients with thyr-
oid dysfunction.
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